In a press release, Novavax said it will sign up 10,000 volunteers between 18 and 84 years of age over the next four to six weeks.
Half of the volunteers will be given a placebo, while the other half will be given two shots of its vaccine.
Up to 400 people will take the vaccine in combination with a seasonal flu vaccine to see how effective a combination both together make.
Novavax said that pre-clinical trials showed its vaccine candidate was “generally well-tolerated” and produced “robust antibody responses.”
The company also said that at least a quarter of volunteers will be over 65 years old, as they want to ensure the trials prioritize those vulnerable to COVID-19. This includes a focus on ethnic minorities too.
Last August, the UK government struck a deal with Novavax, with the government giving the US company support and infrastructure in exchange for Novavax manufacturing the vaccine in the UK and giving Britain 60 million doses if it proves to be safe and effective.
It is the fourth vaccine in the world to enter the final stage of the regulatory process, joining AstraZeneca, Pfizer, and Moderna.
In the UK, it is the second to reach this milestone, following the vaccine being developed by AstraZeneca and Oxford University.
More about: UK coronavirus vaccine
